leisure time -WSS

leisure time

author：focus 2025-09-27 12:36:30 - browse：5411

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Federal judge rules Oregon’s tough new gun law is constitutional

leisure time

WSS

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

Biden administration sends mixed signals on US soldier who crossed into North Korea

A Theranos scientist

Blood tests recalled over risk of missed heart attack diagnosis

A strong 6.5

Congress likely to miss an opportunity to fix drug shortages issue

hotspot

leisure time

focus

Tori Bowie and the unacceptable rates of Black maternal death

Biden administration sends mixed signals on US soldier who crossed into North Korea

Walensky prepares to leave CDC — and Congress — behind

Celiac disease study examines precisely how gluten triggers injury

Medicare details structure of new drug price negotiation program

Does aspartame cause cancer? What new WHO guidance says

How one medical school became remarkably diverse

House passes resolution saying Israel isn't a 'racist or apartheid state'

Hepatitis C has a cure — but many Americans still lack access to it

Woman gored by Bison at Yellowstone

entertainment

Care demand spikes challenge UnitedHealth’s provider arm

Congress: Eradicate hepatitis C and reduce the deficit

Grail faces three suits alleging harassment, retaliation

Does aspartame cause cancer? What new WHO guidance says

Europe sees delivery challenges ahead on Alzheimer's therapies

What we know about the American soldier detained in North Korea

focus

leisure time

focus

knowledge